Chelsea Therapeutics to present at the ThinkEquity Partners 5th Annual Growth Conference

Dr. Simon Pedder, President and CEO of Chelsea Therapeutics, will
provide a brief overview of the company`s product pipeline, clinical
development status and milestone expectations for the remainder of the

Dr. Pedder`s presentation will be webcast live and archived for 90 days on the events page of Chelsea`s website,

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a
variety of human diseases. The Company is currently developing a
library of metabolically inert antifolate compounds engineered to have
potent anti-inflammatory and anti-tumor activity to treat a range of
immunological disorders. Early clinical data suggests that Chelsea`s
lead antifolate compound, CH-1504, is a safe and effective treatment
alternative to methotrexate for RA and may have further applications
for psoriasis, IBD and certain cancers. Chelsea`s antifolate program is
complemented by a strategic partnership with Active Biotech AB for the
joint development of a portfolio of therapeutics targeting
immune-mediated inflammatory disorders and transplantation. In addition
to its autoimmune pipeline, Chelsea is pursing an Orphan Drug strategy
for the development of Droxidopa, an orally active synthetic precursor
of norepinephrine, for the treatment of neurogenic orthostatic
hypotension. Currently approved and marketed in Japan, Droxidopa has
accumulated over 15 years of proven safety and efficacy data,
generating annual revenue of approximately $50 million in Japan.

This press release contains forward-looking statements
regarding future events. These statements are just predictions and are
subject to risks and uncertainties that could cause the actual events
or results to differ materially. These risks and uncertainties include
reliance on collaborations and licenses, risks and costs of drug
development, regulatory approvals, intellectual property risks, our
reliance on our lead drug candidate CH-1504, our history of losses and
need to raise more money, competition, market acceptance for our
products if any are approved for marketing, reliance on key personnel
including specifically Dr. Pedder, management of rapid growth, and the
need to acquire or develop additional products.


Chelsea Therapeutics Nick Riehle,

Chief Financial

704-341-1516 x101

Investor/Media Relations

Kathryn McNeil